Form 4: Vericel Corp: Insider Trades and 10b5-1 Plan Activity

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported transactions involving common stock, including acquisitions under an employee stock purchase plan and sales executed via a Rule 10b5-1 trading plan.

Summary

• Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp (VCEL), reported transactions on June 2, 2026.
• Hopper acquired 4,375 shares of common stock at $16.66 per share under the Issuer's 2015 Employee Stock Purchase Plan.
• These shares were acquired through transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
• Hopper also sold 4,375 shares of common stock at $35 per share.
• These sales were executed as part of an automatic sale pursuant to a Rule 10b5-1 trading plan adopted on May 30, 2025.
• Following these transactions, Hopper beneficially owns 75,753 shares of common stock directly.
• Additionally, Hopper holds stock options representing the right to purchase 1,625 shares of common stock, with a vesting date of May 6, 2019, and an expiration date of February 6, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it reports insider transactions, the sales are executed under a pre-defined 10b5-1 plan, mitigating concerns about opportunistic selling.

Positives

• Acquisition of 4,375 shares under the Employee Stock Purchase Plan indicates continued participation in company equity.
• The sale of shares was conducted under a pre-established Rule 10b5-1 trading plan, suggesting a structured and compliant approach to managing personal stock holdings.
• The stock options held by the reporting person indicate potential future equity ownership and alignment with company performance.

Negatives

• The sale of 4,375 shares at $35 per share, while executed under a 10b5-1 plan, represents a reduction in direct beneficial ownership for the reporting person.

Risks

• The Rule 10b5-1 trading plan is designed to provide an affirmative defense against allegations of insider trading, but its effectiveness relies on proper adoption and execution.
• The sale of shares by a key executive could be interpreted negatively by the market, although the plan is intended to mitigate this.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans by executives is a common and accepted practice for managing personal stock sales in a compliant manner, especially in the biotechnology and medical device sectors where Vericel Corp operates. This filing demonstrates adherence to such established protocols.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, may lead to short-term market perception shifts. However, the acquisition of shares under the ESPP and the continued holding of options suggest ongoing commitment.
• Employees: The acquisition of shares under the Employee Stock Purchase Plan indicates continued employee participation and potential for wealth accumulation through company stock.
• Management: The use of a Rule 10b5-1 plan by the Chief Medical Officer demonstrates adherence to corporate governance best practices for insider trading compliance.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Vericel Corp, VCEL, Stock Options, Employee Stock Purchase Plan, Beneficial Ownership, Jonathan Mark Hopper, SEC Filing